Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Zenith Drugs IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 2000 Industry: Pharmaceuticals & Drugs Listed Page

Profile
Issue Size --
Profile
Price Range 75  to  79 per share
Profile
Min Investment ₹79
Profile
Lot Size 1
Profile
Face Value ₹10
Profile
Draft Prospectus --
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Zenith Drugs Ltd is a pharmaceutical company committed to advancing healthcare through innovative solutions. Established with a focus on research, development, and manufacturing of high-quality pharmaceutical products, Zenith Drugs has gained prominence for its dedication to global well-being. Specializing in a diverse range of therapeutic areas, including cardiovascular, central nervous system, and infectious diseases, the company consistently delivers cutting-edge medications. With a reputation for adherence to stringent quality standards and regulatory compliance, Zenith Drugs Ltd strives to make a positive impact on the health and lives of individuals worldwide. Through a combination of scientific expertise and a customer-centric approach, the company remains at the forefront of the pharmaceutical industry, contributing to advancements in medical treatment and patient care. Read More

Basic Info

Face Value 10 per share

Price 75  to  79 per share

P/E (x) 18.8

Sales( Cr.) 133

PAT( Cr.) 7

EPS 4.2

Draft Prospectus --

Exchange NSE-SME

Promoter

Company Promoters

Mr. Sandeep Bhardwaj Mr. Bhupesh Soni Mr. Ajay Singh Dassundi

Pre Issue Share Holding 100%

Post Issue Share Holding 57.53%

Listing Details:

Listing Price: 110

Listing Gain: 28.18%

Current Price: 48

Gain On Issue: 48 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Feb 19, 2024
Closing Date Feb 22, 2024
Allotment Feb 23, 2024
Refund Feb 26, 2024
Delivery of Shares Feb 26, 2024
Listing Date Feb 27, 2024

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 1600 126,400
Retail (Max) 1 1600 126,400
S-HNI (Min) 2 3200 252,800
S-HNI (Max) 7 11200 884,800
B-HNI (Min) 8 12800 1,011,200

Objective of the Issue

1. Purchase of Machinery and Equipments for Setting up New Unit 2. Existing Manufacturing Block Upgradation 3. Working Capital Requirements 4. General Corporate Purposes.

Issue

Category Nos Bid Bid (x)
QIB 2574400 274739968 106.7x
NII 772320 284808446 368.8x
Retail 1802080 250993702 139.3x
EMP 0 0 0x
Total 5148800 922561984 179.2x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Zenith Drugs Profit & Loss

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 73 92 115 132 133
Other Income 0 1 1 3 3
Total Income 74 93 116 134 136
Total Expenditure 66 85 105 115 119
Operating Profit 7 8 10 19 16
Interest 1 2 2 3 4
Depreciation 1 1 1 1 3
Exceptional Income / Expenses 0 0 0 -2 -0
Profit Before Tax 5 4 7 13 9
Provision for Tax 2 1 2 4 2
Profit After Tax 3 3 5 10 7
Adjustments 0 0 0 0 0
Profit After Adjustments 3 3 5 10 7
Adjusted Earnings Per Share 2.6 2.7 4.1 5.6 4.2

Zenith Drugs Balance Sheet

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 10 13 18 62 69
Minority's Interest 0 0 0 0 0
Borrowings 7 8 8 8 13
Other Non-Current Liabilities 0 0 0 -0 -0
Total Current Liabilities 29 46 72 64 79
Total Liabilities 47 66 97 134 161
Fixed Assets 9 10 11 11 40
Other Non-Current Assets 1 2 2 10 6
Total Current Assets 36 54 84 113 115
Total Assets 47 66 97 134 161

Zenith Drugs Cash Flow

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 2 0 0 9
Cash Flow from Operating Activities -1 5 -4 -16 -5
Cash Flow from Investing Activities -1 -3 -2 -5 -31
Cash Flow from Financing Activities 3 -1 6 30 28
Net Cash Inflow / Outflow 1 1 -0 9 -8
Closing Cash & Cash Equivalent 0 3 0 9 0

Zenith Drugs Ratios

# Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 2.56 2.68 4.07 5.56 4.18
CEPS(Rs) 3.57 3.79 5.15 6.32 5.91
DPS(Rs) 0 0 0 0.5 0
Book NAV/Share(Rs) 8.03 10.71 14.78 36.28 40.46
Core EBITDA Margin(%) 8.87 6.81 7.19 11.04 9.1
EBIT Margin(%) 7.51 6.43 7.14 10.83 8.71
Pre Tax Margin(%) 5.67 4.33 5.19 8.84 6.1
PAT Margin (%) 3.78 3.16 3.81 6.34 4.71
Cash Profit Margin (%) 5.29 4.48 4.83 7.21 6.67
ROA(%) 6.59 5.7 5.97 8.25 4.85
ROE(%) 31.82 28.57 31.92 23.86 10.88
ROCE(%) 24.25 23.87 25.12 25.2 12.96
Receivable days 105.22 99.59 115.89 141.66 153.74
Inventory Days 30.74 34.05 50.99 60 78.54
Payable days 141.12 137.57 275.83 300.96 238.18
PER(x) 0 0 0 11.27 17.17
Price/Book(x) 0 0 0 1.73 1.77
Dividend Yield(%) 0 0 0 0.8 0
EV/Net Sales(x) 0.19 0.16 0.22 0.93 1.28
EV/Core EBITDA(x) 1.92 1.82 2.45 6.41 10.42
Net Sales Growth(%) 0 24.87 24.95 14.93 1.29
EBIT Growth(%) 0 7.29 39.91 78.16 -18.82
PAT Growth(%) 0 4.77 51.92 95.38 -24.92
EPS Growth(%) 0 4.77 51.92 36.72 -24.92
Debt/Equity(x) 1.61 1.31 1.43 0.38 0.7
Current Ratio(x) 1.22 1.18 1.17 1.76 1.45
Quick Ratio(x) 0.99 0.91 0.84 1.36 0.95
Interest Cover(x) 4.08 3.06 3.68 5.43 3.34
Total Debt/Mcap(x) 0 0 0 0.22 0.4

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 1% 13% 0% 0%
Operating Profit CAGR -16% 26% 0% 0%
PAT CAGR -30% 33% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -40% NA% NA% NA%
ROE Average 11% 22% 25% 25%
ROCE Average 13% 21% 22% 22%

Company Contact Information

Zenith Drugs Ltd.

75/1/1 Muradpura (Orangpura) Dhar Road Near Kalariya

IPO Lead Manager(s)

Zenith Drugs Ltd.

Gretex Corporate Services Ltd.

Registrar Info

Zenith Drugs Ltd.

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!